Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management

The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects patient adherence to follow-up, and optimizes the use of imaging and other diagnostic procedures.New analyses from the CLARIFY study, including comparisons and sequencing with PET imaging, add to a growing body of evidence intended to help clinicians identify where Nodify Lung testing can provide the greatest value within the diagnostic pathway. CLARIFY has enrolled more than 2,000 patients who received Nodify Lung testing in routine clinical practice. Additionally, the independent research being presented reflects increasing clinical adoption of Nodify Lung and its role in routine lung nodule management."The growing focus on real-world implementation reflects an important evolution in the evidence supporting Nodify Lung testing," said Scott Hutton, Chief Executive Officer of Biodesix. "The discussion is increasingly moving beyond whether blood-based biomarkers can accurately assess lung nodule risk to how they can be routinely incorporated into structured care pathways and used alongside imaging."Clinical Education and Implementation at CHEST 2026Title: Precision Meets Protocol: Implementing Biomarkers into a Structured Nodule Management Care PathwayLocation: Learning Theater #4Date: Monday, October 19 | 10:15–11:00 am MSTSpeaker: Sonali Sethi, MD, Cleveland ClinicBiodesix-Sponsored Research at CHEST 2026Title: PET Plus Blood-Based Biomarkers vs Biomarkers Alone for Pulmonary Nodule Management: An Inverse Probability of Treatment Weighting Analysis of Real-World EvidenceDate: Tuesday, October 20 | 1:45 pm MSTPresenter: Michael Kammer, PhD, Head of Radiomics, BiodesixTitle: Optimizing Non-invasive Diagnostic Test Sequencing in Pulmonary Nodules: A Counterfactual Analysis of Real-World Data from CLARIFY StudyDate: Tuesday, October 20 | 1:45 pm MSTPresenter: Michael Kammer, PhD, Head of Radiomics, BiodesixTitle: Evaluation of Diagnostic Performance of Tumor-Associated Autoantibodies in Patients with Ground Glass Opacity Pulmonary NodulesDate: Tuesday, October 20 | 1:45 pm MSTPresenter: Michael Kammer, PhD, Head of Radiomics, BiodesixIndependent Nodify Lung Testing Research at CHEST 2026Title: Reducing Loss to Follow-up in Pulmonary Nodules: Proteomics Risk Stratification in a Safety Net Pulmonary ClinicDate: Tuesday, October 20 | 10:34 am MSTPresenter: Arlnaldo Cruz, MD, Wyckoff Heights Medical CenterTitle: Bidirectional Risk Re-Stratification Using Proteomic Biomarker Testing in Two Patients with Identical Pre-Test Malignancy RiskDate: Tuesday, October 20 | 10:20 am MSTPresenter: Jay Xiong, DO, Rosalind Franklin University of Medicine and Science, Aurora Medical Center KenoshaAdditional Lung Diagnostics Research at CHEST 2026Title: Rapid and Concordant EGFR Detection with IQ Lung Liquid Biopsy Compared with Tissue Testing in Stage IVB NSCLC: A Case ReportDate: Tuesday, October 20 | 10:20 am MSTPresenter: Syed Naqvi, MD, Rosalind Franklin University of Medicine and Science, Aurora Medical Center KenoshaBiodesix team members will also be available at Biodesix booth #745 to discuss how blood-based and radiomic biomarkers can support a multimodal approach to lung nodule management and lung health diagnostics.